PILUSO, ALESSIA
 Distribuzione geografica
Continente #
NA - Nord America 2.661
EU - Europa 1.724
AS - Asia 364
OC - Oceania 20
AF - Africa 16
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.786
Nazione #
US - Stati Uniti d'America 2.655
PL - Polonia 636
RU - Federazione Russa 517
IE - Irlanda 160
SE - Svezia 143
IT - Italia 124
CN - Cina 104
SG - Singapore 92
HK - Hong Kong 84
DE - Germania 43
FI - Finlandia 37
GB - Regno Unito 26
IN - India 24
VN - Vietnam 21
AU - Australia 20
UA - Ucraina 17
BE - Belgio 14
JO - Giordania 12
CI - Costa d'Avorio 11
ID - Indonesia 11
TR - Turchia 10
CA - Canada 6
EG - Egitto 4
KR - Corea 4
FR - Francia 3
NL - Olanda 3
JP - Giappone 2
EU - Europa 1
LT - Lituania 1
SC - Seychelles 1
Totale 4.786
Città #
Santa Clara 775
Warsaw 634
Fairfield 275
Chandler 160
Dublin 160
Ashburn 149
Woodbridge 136
Seattle 132
Cambridge 111
Wilmington 109
Houston 100
Ann Arbor 98
Singapore 70
Beijing 62
Altamura 58
Hong Kong 52
Lawrence 50
Princeton 45
Buffalo 38
Bremen 34
Florence 34
Jacksonville 27
Mumbai 24
Medford 23
Boardman 20
Boston 20
Dong Ket 20
Melbourne 20
Shanghai 19
San Diego 16
Brussels 14
Abidjan 11
Falls Church 11
Jakarta 11
New York 10
Izmir 9
Norwalk 9
Old Bridge 7
Andover 6
Washington 5
Avigliano 4
London 4
Phoenix 4
Toronto 4
Ferriere 3
Hillsboro 3
Redmond 3
Bastia umbra 2
Jiaxing 2
Laurel 2
Ottawa 2
Radomsko 2
Rome 2
Brescia 1
Brooklyn 1
Cervia 1
Chiswick 1
Düsseldorf 1
Hangzhou 1
Hanoi 1
Islington 1
Kent 1
Kilburn 1
Los Angeles 1
Moscow 1
Naaldwijk 1
New Bedfont 1
Prescot 1
Raleigh 1
Seoul 1
Shijiazhuang 1
Stockholm 1
Suzhou 1
Tappahannock 1
Wuhan 1
Totale 3.623
Nome #
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 268
Hepatitis C Virus infection in the immunocompromised host: a complex scenario with variable clinical impact 257
Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study 252
Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. 223
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 165
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 165
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 163
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 156
Host genetic determinants in HCV-related mixed cryoglobulinemia 154
A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 150
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 147
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. 143
Host genetic determinants in HCV-related mixed cryoglobulinemia 135
HBV and HCV chronic infection: Autoimmune manifestations and lymphoproliferation 128
HCV-related mixed cryoglobulinemia and BAFF promoter polymorphism 124
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 123
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. 121
Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non- Hodgkin's lymphoma, and cancer 119
Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? 111
Host genetic determinants in HCV-related mixed cryoglobulinemia 111
VALUE OF IL28B GENOTYPING IN PATIENTS WITH HCV-RELATED MIXED CRYOGLOBULINEMIA: RESULTS OF A LARGE, PROSPECTIVE STUDY 109
Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. 107
Circadian Pattern of Serum Leptin and b-Endorphin Levels in Obese and Non Obese Women. 107
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 107
Could the presence of Mixed Cryoglobulinemia influence the outcome of standard peg-IFN plus ribavirin anti-HCV therapy? 92
The role of the rs12979860 polymorphism of the interleukin-28b as predictor of spontaneus clearance of HCV infection in patients with hemophilia 90
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 90
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 89
HCV infection and carotid atherosclerosis: evidence in favour of a local viral action inside the plaque 87
ETIOLOGICAL THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME: THE ROLE OF IL28B GENOTYPE AS PREDICTOR OF RESPONSE 87
HCV-related lymphatic and hepatic malignancies are associated with different microRNA expression patterns in PBMCs 84
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 83
HCV AND lymphoma: Genetic and epigenetic factors 82
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 80
Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26 79
IL28B polymorphism as predictor of response to anti-HCV terapy in HCV-related mixed cryoglobulinemia syndrome 76
Long-term outcome of HCV-related mixed cryoglobulinemia in patients achieving sustained viral sustained viral response (SVR) after antiviral therapy 73
IL28B POLYMORPHISM AS PREDICTOR OF RESPONSE TO ANTI-HCV THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME 70
Totale 4.807
Categoria #
all - tutte 12.139
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.139


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020392 0 0 0 0 0 0 76 84 81 78 66 7
2020/2021495 40 34 24 75 30 49 26 38 48 74 29 28
2021/2022315 3 30 18 20 13 19 9 23 11 13 58 98
2022/2023766 70 126 40 74 61 142 99 44 80 1 21 8
2023/2024209 5 37 44 8 5 25 2 62 4 2 6 9
2024/20251.602 79 198 124 276 630 288 7 0 0 0 0 0
Totale 4.807